Notes from the North: April 2020

In response to news that an anti-viral drug (remdesivir) is showing promise in fast-tracked Phase III trials with COVID-19 patients, the market is ending a strong week on a strong note. This doesn’t change everything, but an effective treatment option would be a blessing, indeed, while we wait for more robust testing capabilities and a vaccine.

The Federal Reserve’s colossal interventions in recent weeks, the focus of this month’s comments, are already old news. It’s a whirlwind.

© 2024 Taylor, Cottrill, Erickson & Associates All Rights Reserved.